Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation (MITRA-FR)
Source: View publication →
In patients with severe secondary mitral regurgitation and heart failure, percutaneous edge-to-edge mitral valve repair added to medical therapy did not reduce the rate of death or unplanned hospitalization for heart failure at 1 year compared to medical therapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MITRA-FR trial demonstrated that in patients with severe left ventricular dilatation and 'proportionate' secondary mitral regurgitation, transcatheter edge-to-edge repair (TEER) does not improve 1-year clinical outcomes over medical therapy alone. This finding emphasized that secondary MR is often a marker of advanced left ventricular dysfunction rather than a primary therapeutic target in this specific phenotype. Contrasted with the subsequent COAPT trial, MITRA-FR was pivotal in establishing the conceptual framework of 'proportionate versus disproportionate' mitral regurgitation to guide patient selection for TEER.
Historical Context
Prior to MITRA-FR, the EVEREST II trial established the safety of the MitraClip system but primarily focused on patients with degenerative (primary) mitral regurgitation. Its efficacy in patients with secondary (functional) mitral regurgitation, where the valve is structurally normal but regurgitation occurs due to left ventricular remodeling and annular dilation, remained unproven. MITRA-FR was the first major randomized controlled trial designed to answer this question. Its completely neutral results initially cast heavy doubt on the use of TEER for secondary MR. However, just weeks later, the COAPT trial reported a dramatic benefit from the same device. The contrasting results ignited intense debate and revolutionized the pathophysiological understanding of secondary MR, leading to the consensus that TEER is highly effective in patients with 'disproportionate' MR (severe MR with less advanced LV dilation, as in COAPT) but ineffective in 'proportionate' MR (moderate/severe MR driven by massive LV dilation, as in MITRA-FR).
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological difference between primary and secondary mitral regurgitation, and why does this distinction matter when considering interventions like edge-to-edge repair?
Key Response
Primary MR involves structural defects of the valve leaflets or chordae, whereas secondary MR is a disease of the left ventricle where dilation and remodeling lead to annular dilation and tethering of structurally normal leaflets. Treating the valve in secondary MR does not fix the underlying severe LV dysfunction, which is why device therapy might not improve systemic outcomes if the ventricle is too dilated.
Before considering percutaneous mitral valve repair for secondary mitral regurgitation, what constitutes guideline-directed medical therapy that must be optimized, and how might it affect the severity of MR?
Key Response
Guideline-directed medical therapy for heart failure with reduced ejection fraction includes beta-blockers, ACEi/ARB/ARNI, MRAs, and SGLT2 inhibitors. Optimizing these agents promotes reverse LV remodeling, which can decrease LV end-diastolic volume, reduce annular dilation and leaflet tethering, and subsequently reduce the severity of secondary MR, potentially averting the need for procedural intervention.
The MITRA-FR trial showed negative results, while the COAPT trial demonstrated significant benefit with MitraClip for secondary MR. How do the differing baseline echocardiographic parameters, specifically EROA and LV end-diastolic volume, between the two trials explain these divergent outcomes?
Key Response
MITRA-FR enrolled patients with larger LV volumes and smaller effective regurgitant orifice areas relative to COAPT, termed 'proportionate MR'. COAPT enrolled patients with smaller LVs and larger EROAs, termed 'disproportionate MR'. Patients in COAPT had MR severity disproportionate to their LV dysfunction, meaning fixing the valve provided a substantial hemodynamic benefit, whereas MITRA-FR patients primarily suffered from severe end-stage LV failure where the MR was merely a bystander.
Given the conflicting results between MITRA-FR and COAPT, how should we approach patient selection for percutaneous edge-to-edge repair in our multidisciplinary Heart Team meetings to ensure we are identifying the right candidates?
Key Response
Patient selection must focus on proving that the mitral regurgitation is the primary driver of symptoms rather than advanced myocardial failure. The Heart Team should ensure maximum tolerated medical and device therapy is achieved first, then carefully review echocardiographic parameters to identify those with severe MR but without excessively dilated or irreversibly damaged ventricles, avoiding the 'too far gone' MITRA-FR phenotype.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In MITRA-FR, medication changes were permitted during the trial, and investigators relied on real-world medical management. How does the lack of a standardized, rigorously enforced medication optimization phase prior to randomization introduce bias, and how could future trial designs control for this dynamic covariate?
Key Response
If medical therapy is not fully optimized before randomization, changes in heart failure medications during the follow-up period can independently drive reverse remodeling, confounding the isolated treatment effect of the transcatheter device. Future designs should employ a standardized run-in phase with a central committee confirming maximal tolerated therapy prior to establishing baseline MR severity and proceeding to randomization.
What are the implications of MITRA-FR utilizing contemporary European rather than American echocardiographic criteria for severe secondary MR, and how does the relatively short one-year primary endpoint follow-up limit the assessment of safety and efficacy?
Key Response
MITRA-FR used European guidelines defining severe MR with an EROA >20 mm2, leading to the inclusion of patients with less severe MR compared to US standards requiring >40 mm2 at the time. This diluted the potential treatment effect. Additionally, a one-year endpoint might fail to capture the long-term LV remodeling effects and potential late device failures or recurrent MR, which are critical for evaluating an irreversible structural intervention.
How should current valvular heart disease guidelines weigh the neutral findings of MITRA-FR against the positive findings of COAPT when determining the Class of Recommendation and Level of Evidence for transcatheter edge-to-edge repair in secondary MR?
Key Response
Current AHA/ACC guidelines synthesize these trials by giving a Class IIa recommendation for TEER only in highly selected patients with severe secondary MR who meet specific 'COAPT-like' criteria (LVEF 20-50 percent, LVESD <= 70mm, PASP <= 70mmHg) while remaining severely symptomatic on optimal GDMT. This explicitly integrates the lessons from MITRA-FR by excluding patients with extreme LV dilation where intervention is deemed futile, thereby restricting the indication rather than offering a blanket approval.
Clinical Landscape
Noteworthy Related Trials
EVEREST II Trial
Tested
Transcatheter mitral-valve repair (MitraClip)
Population
Patients with moderate-to-severe or severe mitral regurgitation (both primary and secondary)
Comparator
Surgical mitral-valve repair or replacement
Endpoint
Composite of freedom from death, from surgery for mitral-valve dysfunction, and from grade 3+ or 4+ mitral regurgitation at 12 months
COAPT Trial
Tested
Transcatheter mitral-valve repair (MitraClip) plus guideline-directed medical therapy
Population
Heart failure patients with severe secondary mitral regurgitation symptomatic despite maximal medical therapy
Comparator
Guideline-directed medical therapy alone
Endpoint
All-cause hospitalizations for heart failure within 24 months
RESHAPE-HF2 Trial
Tested
Transcatheter mitral-valve repair (MitraClip) plus medical therapy
Population
Patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation
Comparator
Medical therapy alone
Endpoint
Composite of first or recurrent heart failure hospitalization or cardiovascular death at 24 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis